Risk factors
Immunome (IMNM) risk factors
Item 1A of every Immunome Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors90 risks23 new4 dropped21 reworded
Immunome faces heavy risks around financing, clinical trial execution, regulatory approval, and building commercial capabilities for products like varegacestat and IM-1021.
Filed Mar 03, 2026 - FY2024 10-K risk factors71 risks
This is Immunome's initial risk disclosure as a public company, reflecting a clinical-stage biotechnology business. Major risks center on clinical trial execution, heavy capital requirements, and heavy reliance on third-party manufacturers. The pipeline features key candidates including varegacestat, IM-1021, and IM-3050.
Filed Mar 19, 2025